Harrow, Inc. (NASDAQ:HROW) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Harrow, Inc. (NASDAQ:HROW - Free Report) by 89.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,940 shares of the company's stock after acquiring an additional 29,262 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.17% of Harrow worth $2,078,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Two Sigma Advisers LP boosted its position in Harrow by 30.4% during the fourth quarter. Two Sigma Advisers LP now owns 38,200 shares of the company's stock worth $1,282,000 after acquiring an additional 8,900 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of Harrow by 483.2% during the 4th quarter. Two Sigma Investments LP now owns 150,355 shares of the company's stock worth $5,044,000 after purchasing an additional 124,574 shares during the period. Rafferty Asset Management LLC purchased a new position in shares of Harrow during the 4th quarter worth $270,000. ProShare Advisors LLC boosted its holdings in shares of Harrow by 30.8% during the fourth quarter. ProShare Advisors LLC now owns 10,289 shares of the company's stock worth $345,000 after purchasing an additional 2,421 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Harrow by 3.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,356 shares of the company's stock worth $582,000 after purchasing an additional 585 shares during the last quarter. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Trading Up 1.9%

Harrow stock traded up $0.56 during midday trading on Monday, reaching $30.15. The stock had a trading volume of 529,025 shares, compared to its average volume of 499,959. The stock's 50-day simple moving average is $25.45 and its 200 day simple moving average is $29.91. Harrow, Inc. has a twelve month low of $16.87 and a twelve month high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The stock has a market capitalization of $1.11 billion, a PE ratio of -32.07 and a beta of 0.40.

Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). The business had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Analysts expect that Harrow, Inc. will post -0.53 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. B. Riley decreased their price target on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. HC Wainwright increased their price objective on shares of Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, May 12th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.